Effects of Programming Parameters on Back Pain Relief in Subthreshold Spinal Cord Stimulation
Primary Purpose
Low Back Pain
Status
Terminated
Phase
Not Applicable
Locations
Australia
Study Type
Interventional
Intervention
Boston Scientific Precision Plus spinal cord stimulation therapy
Sponsored by
About this trial
This is an interventional treatment trial for Low Back Pain
Eligibility Criteria
Inclusion Criteria:
- Chronic intractable pain of the trunk and/or limbs
- Documented history of trunk and/or limb pain of at least 180 days
- Average back pain intensity of 5 or greater on a 0-10 numerical rating scale during the 7-day period prior to the Screening Visit
- Pass study site's routine psychological/psychiatric evaluation within 180 days of the Trial Lead Insertion Visit
- If taking any medications for chronic pain, must be on a stable prescription during the 14-day period prior to the Trial Lead Insertion Visit and agree to continue on the same prescription throughout study participation
- Subject is willing and able to comply with all protocol-required procedures and assessments/evaluations
- Subject is able to independently read and complete all questionnaires and/or assessments provided in English
- 18 years of age or older when written informed consent is obtained
- Subject signs a valid, Ethics Committee-approved informed consent form (ICF) provided in English
Exclusion Criteria:
- Unable to operate the PrecisionPlus™ system
- Primary source of pain is cancer-related, pelvic, visceral, angina, or migraine
- Is a high surgical risk
- Is diabetic
- Is immunocompromised
- Currently on any anticoagulant medications that cannot be discontinued during perioperative period
- Untreated major depression or untreated generalized anxiety disorder
- Diagnosed with somatoform disorder, severe personality disorder, borderline personality disorder
- Diagnosed with any major psychiatric disorder not specifically listed in previous two exclusion criterion
- Currently diagnosed with cognitive impairment that would limit subject's ability to discern differences in pain severity, complete a pain diary, perform wound care
- Current abuse of alcohol or illicit drugs
- Subject requires Magnetic Resonance Imaging (MRI) while implanted with lead(s).
- Subject is participating (or intends to participate) in another investigational drug or device clinical trial that may influence the data that will be collected for this study
- Subject has previously undergone a spinal cord stimulation trial or is already implanted with an active implantable device(s) to treat their pain (IPGs, implantable drug pump, etc) or pacemaker or implantable cardiac defibrillator
- Patient is a woman who is not using adequate contraception, is pregnant or breastfeeding or intends to become pregnant during the course of the study (a urine pregnancy test must be performed within 28 days prior to the Trial Lead Insertion Visit in women of child-bearing potential and the test result document)
Sites / Locations
- Hunter Pain Clinic
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Active Comparator
Experimental
Arm Label
Sham Stimulation
Treatment 1
Treatment 2
Arm Description
Sham subthreshold spinal cord stimulation therapy
subthreshold spinal cord stimulation therapy
subthreshold spinal cord stimulation therapy
Outcomes
Primary Outcome Measures
Pain Relief
Mean within-patient difference in average back pain intensity among treatment groups
Secondary Outcome Measures
Pain Relief Responder Rate
Difference in the proportion of subjects with ≥50% reduction in average back pain intensity among treatment groups
Leg Pain Reduction
Mean within-patient difference in average leg pain intensity among treatment groups
Disability
Mean within-patient difference in disability among treatment groups
Percent Pain Relief
Mean within-patient difference in overall percent pain relief among treatment groups
Quality of Life, as Measured by EQ-5D-5L
Mean within-patient difference in quality of life among treatment groups
Full Information
NCT ID
NCT01550562
First Posted
February 15, 2012
Last Updated
March 31, 2021
Sponsor
Boston Scientific Corporation
1. Study Identification
Unique Protocol Identification Number
NCT01550562
Brief Title
Effects of Programming Parameters on Back Pain Relief in Subthreshold Spinal Cord Stimulation
Official Title
Precision™ High-Rate Sub-perception Spinal Cord Stimulation for the Treatment of Chronic Intractable Pain
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Terminated
Why Stopped
In >9 months only 1 patient enrolled. Study stopped because design was too cumbersome and subjects not willing to participate
Study Start Date
February 2012 (Actual)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
April 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boston Scientific Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to investigate the effects of varying programming parameters in subthreshold spinal cord stimulation therapy for pain relief.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Low Back Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
1 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sham Stimulation
Arm Type
Placebo Comparator
Arm Description
Sham subthreshold spinal cord stimulation therapy
Arm Title
Treatment 1
Arm Type
Active Comparator
Arm Description
subthreshold spinal cord stimulation therapy
Arm Title
Treatment 2
Arm Type
Experimental
Arm Description
subthreshold spinal cord stimulation therapy
Intervention Type
Device
Intervention Name(s)
Boston Scientific Precision Plus spinal cord stimulation therapy
Intervention Description
Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
Primary Outcome Measure Information:
Title
Pain Relief
Description
Mean within-patient difference in average back pain intensity among treatment groups
Time Frame
4,8,and 12 days post temporary lead(s) implantation
Secondary Outcome Measure Information:
Title
Pain Relief Responder Rate
Description
Difference in the proportion of subjects with ≥50% reduction in average back pain intensity among treatment groups
Time Frame
4,8,and 12 days post temporary lead(s) implantation
Title
Leg Pain Reduction
Description
Mean within-patient difference in average leg pain intensity among treatment groups
Time Frame
4,8,and 12 days post temporary lead(s) implantation
Title
Disability
Description
Mean within-patient difference in disability among treatment groups
Time Frame
4,8,and 12 days post temporary lead(s) implantation
Title
Percent Pain Relief
Description
Mean within-patient difference in overall percent pain relief among treatment groups
Time Frame
4,8,and 12 days post temporary lead(s) implantation
Title
Quality of Life, as Measured by EQ-5D-5L
Description
Mean within-patient difference in quality of life among treatment groups
Time Frame
4,8,and 12 days post temporary lead(s) implantation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Chronic intractable pain of the trunk and/or limbs
Documented history of trunk and/or limb pain of at least 180 days
Average back pain intensity of 5 or greater on a 0-10 numerical rating scale during the 7-day period prior to the Screening Visit
Pass study site's routine psychological/psychiatric evaluation within 180 days of the Trial Lead Insertion Visit
If taking any medications for chronic pain, must be on a stable prescription during the 14-day period prior to the Trial Lead Insertion Visit and agree to continue on the same prescription throughout study participation
Subject is willing and able to comply with all protocol-required procedures and assessments/evaluations
Subject is able to independently read and complete all questionnaires and/or assessments provided in English
18 years of age or older when written informed consent is obtained
Subject signs a valid, Ethics Committee-approved informed consent form (ICF) provided in English
Exclusion Criteria:
Unable to operate the PrecisionPlus™ system
Primary source of pain is cancer-related, pelvic, visceral, angina, or migraine
Is a high surgical risk
Is diabetic
Is immunocompromised
Currently on any anticoagulant medications that cannot be discontinued during perioperative period
Untreated major depression or untreated generalized anxiety disorder
Diagnosed with somatoform disorder, severe personality disorder, borderline personality disorder
Diagnosed with any major psychiatric disorder not specifically listed in previous two exclusion criterion
Currently diagnosed with cognitive impairment that would limit subject's ability to discern differences in pain severity, complete a pain diary, perform wound care
Current abuse of alcohol or illicit drugs
Subject requires Magnetic Resonance Imaging (MRI) while implanted with lead(s).
Subject is participating (or intends to participate) in another investigational drug or device clinical trial that may influence the data that will be collected for this study
Subject has previously undergone a spinal cord stimulation trial or is already implanted with an active implantable device(s) to treat their pain (IPGs, implantable drug pump, etc) or pacemaker or implantable cardiac defibrillator
Patient is a woman who is not using adequate contraception, is pregnant or breastfeeding or intends to become pregnant during the course of the study (a urine pregnancy test must be performed within 28 days prior to the Trial Lead Insertion Visit in women of child-bearing potential and the test result document)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kay Adair
Organizational Affiliation
Boston Scientific Corporation
Official's Role
Study Director
Facility Information:
Facility Name
Hunter Pain Clinic
City
Newcastle
State/Province
New South Wales
ZIP/Postal Code
2292
Country
Australia
12. IPD Sharing Statement
Learn more about this trial
Effects of Programming Parameters on Back Pain Relief in Subthreshold Spinal Cord Stimulation
We'll reach out to this number within 24 hrs